Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTSNASDAQ:EVOKNASDAQ:NERVNASDAQ:ONCR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSBiophytis$8.22-15.3%$16.35$8.05▼$168.80$2.88M1.057,284 shs17,953 shsEVOKEvoke Pharma$0.44-2.6%$0.60$0.42▼$2.40$3.70M0.2253,776 shs15,641 shsNERVMinerva Neurosciences$2.43-3.6%$3.48$2.29▼$13.49$16.99M0.21101,123 shs5,770 shsONCROncorus$0.13-3.1%$0.07$0.01▼$0.47$3.29M3.61.33 million shs135,900 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSBiophytis-4.81%-13.05%-35.47%-50.51%-92.85%EVOKEvoke Pharma+0.90%-18.49%-24.15%-30.83%-76.93%NERVMinerva Neurosciences-0.40%+2.02%-5.26%-67.32%+8.15%ONCROncorus0.00%0.00%0.00%0.00%-62.94%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTSBiophytis2.2864 of 5 stars3.55.00.00.01.70.00.6EVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.0939 of 5 stars3.03.00.04.61.70.00.0ONCROncorusN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSBiophytis3.00Buy$600.007,199.27% UpsideEVOKEvoke PharmaN/AN/AN/AN/ANERVMinerva Neurosciences2.00Hold$11.00352.67% UpsideONCROncorusN/AN/AN/AN/ACurrent Analyst RatingsLatest EVOK, ONCR, BPTS, and NERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/27/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$11.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSBiophytisN/AN/AN/AN/A($17.29) per shareN/AEVOKEvoke Pharma$5.18M0.71N/AN/A($0.77) per share-0.57NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AONCROncorusN/AN/AN/AN/A$2.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSBiophytis-$18.43MN/A0.00N/AN/AN/AN/AN/AN/AEVOKEvoke Pharma-$7.79M-$2.33N/A∞N/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)NERVMinerva Neurosciences-$30M-$4.65N/AN/AN/AN/AN/A-50.27%5/20/2024 (Estimated)ONCROncorus-$77.42M-$3.49N/A∞N/AN/AN/AN/AN/ALatest EVOK, ONCR, BPTS, and NERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023EVOKEvoke PharmaN/A-$0.59-$0.59-$0.59N/A$1.68 million 2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSBiophytisN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AONCROncorusN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSBiophytisN/A0.720.72EVOKEvoke PharmaN/A2.252.09NERVMinerva NeurosciencesN/A12.5712.58ONCROncorusN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSBiophytis0.05%EVOKEvoke PharmaN/ANERVMinerva Neurosciences34.56%ONCROncorus20.07%Insider OwnershipCompanyInsider OwnershipBPTSBiophytis3.70%EVOKEvoke Pharma11.78%NERVMinerva Neurosciences6.40%ONCROncorus17.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTSBiophytis26350,000338,000Not OptionableEVOKEvoke Pharma48.48 million7.48 millionNot OptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionableONCROncorus6426.09 million21.63 millionOptionableEVOK, ONCR, BPTS, and NERV HeadlinesSourceHeadlineOncorus Inc rdinary Shares Stock (OTC:ONCR) Dividends: History, Yield and Datesbenzinga.com - February 26 at 5:39 PMOncorus, Inc. (ONCR) stock price, news, quote & history – Yahoo Financeuk.finance.yahoo.com - December 29 at 5:58 PMComera Life Sciences Holdings Incinvesting.com - December 18 at 12:34 AMOncorus Inc Ordinary Sharesmorningstar.com - October 28 at 1:38 PMONCR Historical Datainvesting.com - October 16 at 9:10 AMOncorus Inc. (ONCR) receives a Buy rating from Maxim Groupknoxdaily.com - June 21 at 12:17 PMTaking a look at what insiders are doing to gauge the Oncorus Inc. (ONCR)’s directionknoxdaily.com - June 16 at 4:55 PMWhat's Going On With Oncorus (ONCR) Stock Friday?msn.com - June 16 at 4:55 PMMaxim Group gives a Buy recommendation for Oncorus Inc. (ONCR)knoxdaily.com - June 15 at 2:09 AMONCR price target predicted to rise nearly $1.50 in 12 monthsknoxdaily.com - June 9 at 1:12 PMOncorus could file for bankruptcy as most employees laid off; down 43%msn.com - June 2 at 1:24 PMDays-to-cover ratio for ONCR declines to 2.51 due to decline in short interestknoxdaily.com - June 1 at 10:23 PMOncorus Announces Workforce Reduction Planfinance.yahoo.com - June 1 at 5:22 PMOncorus, Inc.: Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - May 23 at 8:46 AMRecap: Oncorus Q1 Earningsmsn.com - May 22 at 11:01 PMOncorus Reports First Quarter 2023 Financial Results and Provides Business Updatesfinance.yahoo.com - May 22 at 6:00 PMOncorus, Inc.: Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updatesfinanznachrichten.de - March 24 at 10:04 AMOncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updatesfinance.yahoo.com - March 24 at 10:04 AMFor some biotechs moving on from SVB, not all traditional banks are an optionbizjournals.com - March 15 at 3:11 PMRoku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bankmarkets.businessinsider.com - March 11 at 5:05 PMOncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidatesfinance.yahoo.com - January 4 at 7:32 AMOncorus Shares Plumb New Depths on Job Cuts, Portfolio Reshaping >ONCRmarketwatch.com - November 30 at 2:36 PMOncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA ...elpasoinc.com - November 30 at 7:46 AMOncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancerfinance.yahoo.com - November 30 at 7:46 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiophytisNASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Evoke PharmaNASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.OncorusNASDAQ:ONCROncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.